Log in to search using one of your social media accounts:

 

What to do with success? The optimist’s creed in relapsed Hodgkin lymphoma
Checkpoint inhibitors have demonstrated remarkable efficacy in patients with chemotherapy resistant Hodgkin lymphoma. However, it remains unclear if these impressive agents have curative potential, or if relapse and death will eventually occur. In this review, we discuss the options for a therapeutic dilemma which is likely to occur with increasing frequency, what to do for a Hodgkin lymphoma patient who is responding the checkpoint inhibitors? We discuss the four most likely considered options: continuation of checkpoint blockade, cessation of therapy with potential re-treatment, transplantation, and chimeric antigen rece...
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Amir Issa, Jason Westin Tags: Perspective Source Type: research

Post-transplantation NK Cell Count: A Predictor of Acute GVHD and Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation
Reconstitution of the immune system after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is important in transplant outcomes. We retrospectively analyzed data from 70 patients who underwent allo-HSCT with lymphocytes subset (LST) results. And the association between LST counts with early complications and outcomes after allo-HSCT was analyzed. NK cell counts after allo-HSCT were predictive of acute GVHD, NRM and survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Seo Yeon Kim, Hyewon Lee, Mi-Soon Han, Hyoeun Shim, Hyeon-Seok Eom, Boram Park, Sun-Young Kong Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 31, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 31, 2016 Category: Hematology Source Type: research

Optimizing the Use of TKIs in the Management of Chronic Myelogenous Leukemia
The objective of this study was to evaluate the performance of clinicians on multiple aspects of CML management and to target any identified proficiency gaps. The results demonstrated the benefits of s serial learning approach as participants who completed multiple activities achieved the greatest clinical performance gains from baseline. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 8, 2016 Category: Hematology Authors: Karyn Ruiz-Cordell, Steven Haimowitz, Linda Gracie-King, Deborah Middleton Tags: Original Study Source Type: research

Clinical Implications of CD30 Expression in Aggressive B-cell Lymphomas
FDA approval of Brentuximab for treatment of CD30+ relapsed/refractory lymphomas initiated research focused on CD30 expression in lymphomas. Several studies examined CD30 expression in subsets of DLBCL. In our study we have expanded this research by studying CD30 expression in other types of aggressive B-cell lymphomas, including Burkitt lymphomas, high grade Follicular Lymphomas, FL3/DLBCL, DLBCL type PTLDs and PMBLs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 8, 2016 Category: Hematology Authors: Jozef Malysz, Patrick Erdman, Jeremy Klapper, Junjia Zhu, Michael Creer, Michael G. Bayerl Tags: Original Study Source Type: research

Cyclophosphamide and bortezomib with prednisone or dexamethasone for the treatment of relapsed and refractory multiple myeloma
Clinical trials of the combination of cyclophosphamide, bortezomib and steroids in relapsed/refractory myeloma have shown promising results, but there is little information about real-world outcomes. We retrospectively reviewed the results of weekly CyBorP(D) in 96 patients treated off study. The overall response rate was 69%; median PFS was 16.2 months. Toxicity was mild with low rates of myelosuppression and neuropathy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 8, 2016 Category: Hematology Authors: Donna E. Reece, Young Trieu, Esther Masih-Khan, Eshetu G. Atenafu, Christine Chen, Anca Prica, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti Tags: Original Study Source Type: research

Validation and Utility of the Free Light Chain Assay in Pleural Effusions of Patients With Multiple Myeloma
Although multiple myeloma (MM) is a bone marrow disorder, ≤ 20% of patients will ultimately develop extramedullary disease that can involve virtually any organ.1,2 Pleural effusions are also a relatively uncommon occurrence in MM (incidence of 6%)1 and are most often complications of infection or dysproteinemia, such as nephritic syndromes, congestive heart failure secondary to amyloidosis, or mediastinal lymphatic obstruction. The findings from case reports and larger studies have suggested myelomatous pleural effusions (MPEs) will be present in only 1% to 2% of MM patients,3,4 and the diagnosis of MPE is ominous,...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Thomas U. Marron, Matthew G. Hanna, Lakshmi Ramanathan, Ajai Chari Tags: Case Report Source Type: research

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
Relapse is the major cause of allogeneic hematopoietic stem cell transplantation failure in high-risk Philadelphia chromosome-positive (Ph+) leukemia. Post-transplant maintenance therapy is a promising strategy. We found maintenance imatinib and dose-reduced newer generation tyrosine kinase inhibitors to be feasible and generally well tolerated. This approach might reduce the incidence of relapse and improve the outcomes after allogeneic hematopoietic stem cell transplantation for high-risk Ph+ leukemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Zachariah DeFilipp, Amelia A. Langston, Zhengjia Chen, Chao Zhang, Martha L. Arellano, Fuad El Rassi, Christopher R. Flowers, Vamsi K. Kota, Zaid Al-Kadhimi, Rachel Veldman, Anand P. Jillella, Sagar Lonial, Edmund K. Waller, Hanna J. Khoury Tags: Original Study Source Type: research

Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country
Our aim was to assess the routine use of fluorescent in situ hybridization in the monitoring of chronic phase chronic myeloid leukemia. We retrospectively analyzed data from 63 patients. The monitoring adherence assessment revealed better compliance rates compared with previous reports. Excellent correlation between fluorescent in situ hybridization and chromosome banding analysis was found. Achieving a complete cytogenetic response, assessed by fluorescent in situ hybridization, was an independent prognostic factor in the outcomes of patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Christianne Bourlon, Carlos Hernandez-Mata, Cesar Vargas-Serafín, María T. Bourlon, Elena Tuna-Aguilar, Alvaro Aguayo Tags: Original Study Source Type: research

Letter to the Editor
We read with interest the report by Subari et al1 in which they evaluated the difference in survival outcomes between therapy-related chronic myelomonocytic leukemia (CMML) and de novo CMML. They revealed that patients with therapy-related CMML had poorer survival than those with de novo CMML (median overall survival [OS], 11 vs. 20 months; P = .02). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Mohamed Abd El-Fattah Tags: Letter to the Editor Source Type: research

Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study
Imatinib has been the standard of care in chronic myelogenous leukemia for 15 years. Its optimal plasma concentration correlates with optimal disease response. We compared plasma concentrations in patients who switched from branded to generic imatinib. No statistical difference in achieved imatinib plasma concentrations was found, and the treatment response was maintained. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Alen Ostojic, Dubravka Sertic, Pavle Roncevic, Zinaida Peric, Paula Granic, Nikolina Matic, Sandra Basic-Kinda, Ranka Serventi-Seiwerth, Ivo Radman, Renata Zadro, Damir Nemet Tags: Original Study Source Type: research

Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature
Symptoms of peripheral neuropathy are very common, with conventional estimates of prevalence in the United States in the tens of millions. Approximately 10% of patients with a polyneuropathy of unknown cause have a coexistent monoclonal gammopathy. Many of these are incidental gammopathies, unrelated to the neuropathy. However, there are numerous entities in which the gammopathy induces the neuropathy, and is therefore the prime target for therapy (eg, amyloidosis, Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS), immunoglobulin [Ig]M deposition disease, etc). (Source: Clinical ...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Alexandra Gomez, James E. Hoffman Tags: Case Report Source Type: research

Fluorescent in situ hybridization monitoring and impact of detected early responses in the outcome of CP-CML patients: a report of a Latin American country
Our aim was to assess the routine use of fluorescent in situ hybridization (FISH) in the monitoring of chronic phase chronic myeloid leukemia (CP-CML). We retrospectively analyzed data from 63 patients. The monitoring adherence assessment revealed better compliance rates compared to previous reports. Excellent correlation between FISH and chromosome banding analysis (CBA) was found. Achieving a complete cytogenetic response (CCyR), assessed by FISH, was an independent prognostic factor in the outcome of patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Christianne Bourlon, Carlos Hernandez-Mata, Cesar Vargas-Serafín, María T. Bourlon, Elena Tuna-Aguilar, Alvaro Aguayo Tags: Original Study Source Type: research

Comparison of branded and generics imatinib plasma concentrations in patients with chronic myelogenous leukemia – unicentric study
Imatinib has been the standard of care in chronic myelogenous leukemia for fifteen years. Its optimal plasma concentration correlates with optimal disease response. We compared plasma concentrations in patients who switched from branded to generic imatinib. No statistical difference in achieved imatinib plasma concentrations was found, and the treatment response was maintained. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Alen Ostojic, Dubravka Sertic, Pavle Roncevic, Zinaida Peric, Paula Granic, Nikolina Matic, Sandra Basic-Kinda, Ranka Serventi-Seiwerth, Ivo Radman, Renata Zadro, Damir Nemet Tags: Original Study Source Type: research

Anti Myelin-Associated-Glycoprotein (MAG) antibody peripheral neuropathy response to combination chemoimmunotherapy with Bendamustine - Rituximab in a patient with biclonal IgM kappa and IgM lambda gammopathy: Case report and review of the literature
Symptoms of peripheral neuropathy are very common, with conventional estimates of prevalence in the United States in the tens of millions. Approximately ten percent of patients with a polyneuropathy of unknown cause have a coexistent monoclonal gammopathy. Many of these are incidental gammopathies, unrelated to the neuropathy. However, there are numerous entities wherein the gammopathy induces the neuropathy, and is therefore the prime target for therapy (e.g. amyloidosis, POEMS, IgM deposition disease etc). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Alexandra Gomez, James E. Hoffman Tags: Case Report Source Type: research

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120
We describe 3 patients with relapsed/refractory acute myeloid leukemia who developed clinically-apparent differentiation concurrent with clinical response during monotherapy with AG-120, a novel, oral inhibitor of mutant isocitrate dehydrogenase 1. Symptoms included marked leukocytosis and exuberant neutrophil recovery among other clinically-apparent constitutional manifestations. Awareness of the potential for differentiation syndrome with such inhibitors, and prompt identification and intervention, are essential to facilitate clinical resolution. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Birendra KC, Courtney D. DiNardo Tags: Original Study Source Type: research

Autologous stem cell mobilization in the age of plerixafor
Plerixafor is a potent stem cell mobilizing agent whose cost is prohibitive for routine use. In 277 consecutive patients, the addition of rescue plerixafor during suboptimal G-CSF mobilization or after prior failure of chemotherapy plus G-CSF, was associated with successful mobilization in 97.5% of patients with target collections achieved in 60% of lymphoma and 72% of myeloma patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Dennis L. Cooper, Erin Medoff, Natalie Patel, Julie Baker, Kathryn Pratt, Francine Foss, Stuart E. Seropian, Sarah Perreault, Yanyun Wu Tags: Original Study Source Type: research

Validation and utility of the free light chains assay in pleural effusions of patients with multiple myeloma
Although multiple myeloma (MM) is a bone marrow disorder, up to twenty percent of patients will ultimately develop extramedullary (EM) disease that can involve virtually any organ.1,2 Pleural effusions are also a relatively uncommon occurrence in MM (incidence of 6%)1, and are most often complications of infection or dysproteinemia such as nephritic syndromes, congestive heart failure secondary to amyloidosis, or mediastinal lymphatic obstruction. Case reports and larger studies suggest myelomatous pleural effusions (MPEs) to be present in only 1-2% of MM patients3,4, and the diagnosis of MPE is ominous, with a median life...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Thomas U. Marron, Matthew G. Hanna, Lakshmi Ramanathan, Ajai Chari Tags: Case Report Source Type: research

Clinical features and treatment outcomes of patients with Necrobiotic Xanthogranuloma associated with monoclonal gammopathies
Necrobiotic xanthogranuloma (NXG) is a rare chronic granulomatous disorder of the skin associated with a monoclonal gammopathy. This is a single tertiary medical center retrospective study which describes the clinical features of 35 patients with NXG and monoclonal gammopathy as well as their subsequent disease course and response to treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Larissa S. Higgins, Ronald S. Go, David Dingli, Shaji K. Kumar, S. Vincent Rajkumar, Angela Dispenzieri, Francis K. Buadi, Martha Q. Lacy, John A. Lust, Prashant Kapoor, Nelson Leung, Yi Lin, Taxiarchis V. Kourelis, Morie A. Gertz, Robert A. Kyle, Wilson Tags: Original Study Source Type: research

Treatment with Doxycycline for Severe Bortezomib-associated Blepharitis
Blepharitis is an inflammatory condition of the eyelid margin and is a common cause of ocular and visual discomfort. It is defined as anterior blepharitis, when affecting the eyelid skin and eyelash follicles, or posterior blepharitis, when involving the meibomian glands.1 Chalazia may develop as a result of lipogranulomatous collection in the meibomian glands. In severe cases, trichiasis and keratitis may occur.2,3 Blepharitis is associated with Staphylococcus aureus colonization, infestation with parasites, meibomian gland dysfunction, rosacea, seborrheic dermatitis, topical use of prostaglandin analogues and systemic us...
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Marie-Charlotte Veys, Michel Delforge, Ilse Mombaerts Tags: Case Report Source Type: research

Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia
Mutations in CXCR4 have been identified in ∼29% of Waldenstrom Macroglobulinemia patients having the MYD88L265P mutation. CXCR4 mutations interfere with treatment response to ibrutinib. We designed and validated Sanger sequencing and pyrosequencing assays to detect mutations in CXCR4 in a CLIA-approved clinical laboratory. We identified CXCR4 mutations in 8/33 low grade B-cell lymphomas examined. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Leomar Y. Ballester, Sanam Loghavi, Rashmi Kanagal-Shamanna, Bedia A. Barkoh, Pei Lin, L. Jeffrey Medeiros, Rajyalakshmi Luthra, Keyur P. Patel Tags: Original Study Source Type: research

Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of high-risk Philadelphia chromosome-positive leukemia?
Relapse is the major cause of allogeneic hematopoietic stem cell transplantation (HSCT) failure in high-risk Philadelphia chromosome-positive (Ph+) leukemia. Post-transplant maintenance therapy is a promising strategy. We found maintenance imatinib and dose-reduced newer generation tyrosine kinase inhibitors to be feasible and generally well tolerated. This approach may reduce relapse and improve outcomes following allogeneic HSCT for high-risk Ph+ leukemia. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Zachariah DeFilipp, Amelia A. Langston, Zhengjia Chen, Chao Zhang, Martha L. Arellano, Fuad El Rassi, Christopher R. Flowers, Vamsi K. Kota, Zaid Al-Kadhimi, Rachel Veldman, Anand P. Jillella, Sagar Lonial, Edmund K. Waller, Hanna J. Khoury Tags: Original Study Source Type: research

Clinical prognostic factors and survival outcome of chronic myelomonocytic leukemia: reviewing 3,686 patients
We read with interest the paper of Subari et al1 in which they evaluated the difference of survival outcome between therapy-related chronic myelomonocytic leukemia (CMML) and De Novo CMML. They revealed that therapy-related CMML patients had poorer survival than De Novo CMML (median OS; 11 vs. 20 months, p=0.02). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Mohamed Abd El-Fattah Tags: Letter to the Editor Source Type: research

Diversities of Calreticulin Gene Mutations in Macedonian Patients with Essential Thrombocythemia
A wide range of different CALR mutations were detected in 150 Macedonian patients with essential thrombocythemia which were associated with distinct clinical phenotype with a milder clinical course of the disease compared to patients with JAK2 V617F mutation. Polymerase chain reaction /capillary electrophoresis is the method of choice for the analysis of CALR mutations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 4, 2016 Category: Hematology Authors: Irina Panovska-Stavridis, Aleksandar Eftimov, Martin Ivanovski, Aleksandar Stojanovik, Borce Georgievski, Lidija Cevreska, Aleksandar J. Dimovski Tags: Original Study Source Type: research

Volume –Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy
A volume –outcome relationship has been shown in adult oncology. We investigated if an inverse association of volume and death exists in pediatric acute lymphoblastic leukemia (ALL) care. In assessing the association of volume and outcomes in a cohort of hospitalized pediatric ALL patients, we did not show an inverse relationship between volume and mortality or need for intensive care. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2016 Category: Hematology Authors: Jennifer J. Wilkes, Sean Hennessy, Rui Xiao, Susan Rheingold, Alix E. Seif, Yuan-Shung Huang, Neika Vendetti, Yimei Li, Rochelle Bagatell, Richard Aplenc, Brian T. Fisher Tags: Original Study Source Type: research

Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of peripheral T-cell lymphoma (PTCL) with limited studies. We used the Surveillance, Epidemiology, and End Results 18 registry to identify a cohort of unselected patients with SPTCL and compared its outcomes with patients with PTCL not otherwise specified (NOS), the most common subtype among all PTCL. The overall survival of SPTCL was much better than PTCL NOS even after matching for potential confounders including age at diagnosis, year of diagnosis, sex, marital status, and race. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2016 Category: Hematology Authors: Vijaya Raj Bhatt, Smith Giri, Vivek Verma, Samyak Manandhar, Ranjan Pathak, R. Gregory Bociek, Julie M. Vose, James O. Armitage Tags: Original Study Source Type: research

Prognostic Effect of Low Subcutaneous Adipose Tissue on Survival Outcome in Patients With Multiple Myeloma
We retrospectively analyzed the volume of skeletal muscle and adipose tissue in 56 patients with newly diagnosed symptomatic multiple myeloma (MM) at a single institute. Low volume of subcutaneous adipose tissue was associated with poor overall survival (hazard ratio, 4.05; P = .02). Results of this study might indicate that a low volume of subcutaneous adipose tissue at baseline is an independent prognostic factor in patients with MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2016 Category: Hematology Authors: Yasunobu Takeoka, Kazuki Sakatoku, Akiko Miura, Ryosuke Yamamura, Taku Araki, Hirotaka Seura, Terue Okamura, Hideo Koh, Hirohisa Nakamae, Masayuki Hino, Kensuke Ohta Tags: Original Study Source Type: research

Volume–Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy
A volume–outcome relationship has been shown in adult oncology. We investigated if an inverse association of volume and death exists in pediatric acute lymphoblastic leukemia (ALL) care. In assessing the association of volume and outcomes in a cohort of hospitalized pediatric ALL patients, we did not show an inverse relationship between volume and mortality or need for intensive care. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2016 Category: Hematology Authors: Jennifer J. Wilkes, Sean Hennessy, Rui Xiao, Susan Rheingold, Alix E. Seif, Yuan-Shung Huang, Neika Vendetti, Yimei Li, Rochelle Bagatell, Richard Aplenc, Brian T. Fisher Tags: Original Study Source Type: research

Prognostic Impact of Low Subcutaneous Adipose Tissue on Survival Outcome in Patients with Multiple Myeloma
This study may indicate that low subcutaneous adipose tissue at baseline is an independent prognostic factor in patients with MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2016 Category: Hematology Authors: Yasunobu Takeoka, Kazuki Sakatoku, Akiko Miura, Ryosuke Yamamura, Taku Araki, Hirotaka Seura, Terue Okamura, Hideo Koh, Hirohisa Nakamae, Masayuki Hino, Kensuke Ohta Tags: Original Study Source Type: research

Survival of subcutaneous panniculitis-like T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified: A propensity matched analysis of the Surveillance, Epidemiology and End Results database
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of Peripheral T-cell lymphoma (PTCL) with limited studies. We utilized the Surveillance, Epidemiology and End Results (SEER) 18 registry to identify a cohort of unselected patients with SPTCL and compared its outcomes with PTCL, Not Otherwise Specified (NOS), the most common subtype among all PTCL. The overall survival of SPTCL was much better than PTCL, NOS even after matching for potential confounders including age at diagnosis, year of diagnosis, gender, marital status and race. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2016 Category: Hematology Authors: Vijaya Raj Bhatt, Smith Giri, Vivek Verma, Samyak Manandhar, Ranjan Pathak, R. Gregory Bociek, Julie M. Vose, James O. Armitage Tags: Original Study Source Type: research

Volume - Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association between Hospital Pediatric and Pediatric Oncology Volume with Mortality and Intensive Care Resources during Initial Therapy
A volume-outcome relationship has been demonstrated in adult oncology. We investigated if an inverse association of volume and death exists in pediatric acute lymphoblastic leukemia (ALL) care. In assessing the association of volume and outcomes in a cohort of hospitalized pediatric ALL patients, we did not demonstrate an inverse relationship between volume and mortality or need for intensive care. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - May 3, 2016 Category: Hematology Authors: Jennifer J. Wilkes, Sean Hennessy, Rui Xiao, Susan Rheingold, Alix E. Seif, Yuan-Shung Huang, Neika Vendetti, Yimei Li, Rochelle Bagatell, Richard Aplenc, Brian T. Fisher Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 30, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 30, 2016 Category: Hematology Source Type: research

Evaluation of patients and families with concern for predispositions to hematologic malignancies within the Hereditary Hematologic Malignancy Clinic (HHMC)
The clinical importance and anticipated results of genetic counseling and testing for hereditary cancer syndromes in patients with hematologic malignancies is poorly defined. We evaluated 67 patients referred to the Hereditary Hematologic Malignancy Clinic at a single institution. A cancer predisposition syndrome was confirmed in twelve patients (18%). Identification of germline predispositions to malignancy provides insight for individualized treatment, and screening/surveillance opportunities for family members. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 27, 2016 Category: Hematology Authors: Courtney D. DiNardo, Sarah A. Bannon, Mark Routbort, Anna Franklin, Maureen Mork, Mary Armanios, Emily M. Mace, Jordan S. Orange, Meselle Jeff-Eke, Jane E. Churpek, Koichi Takahashi, Jeffrey L. Jorgensen, Guillermo Garcia-Manero, Steve Kornblau, Alison Be Tags: Original Study Source Type: research

Adherence to Monitoring Tests in Patients With Chronic Myeloid Leukemia in Lebanon
The present study was performed to determine whether the adherence to regular follow-up assessments using standardized real-time quantitative polymerase chain reaction (qPCR) and/or cytogenetic tests in Lebanese patients with chronic myeloid leukemia (CML) meet the European LeukemiaNet recommendations. The present study was a retrospective analysis of 34 patients diagnosed with chronic phase CML who had been treated with tyrosine kinase inhibitors and monitored with regular cytogenetic tests and/or measurement of the BCR-ABL transcript level at 3, 6, and 12 months from 2006 until 2015 in 3 university hospitals in Lebanon. ...
Source: Clinical Lymphoma, Myeloma and Leukemia - April 3, 2016 Category: Hematology Authors: Marcel Massoud, Fadi Nasr, Riwa Sakr, Jenny Hawi, Fouad Kerbage, Georges Chahine Tags: SOHO Supplement 2016 Source Type: research

Adherence to monitoring tests in CML patients in Lebanon
During the last 15 years, the chronic oral administration of tyrosine kinase inhibitor (TKI) drug which specifically targeted the tyrosine kinase activity of the oncogenic proteins encoded by BCR/ ABL1, (1) rapidly and dramatically modified the treatment of CML, which led to important changes in the management of the disease (2) and revolutionized the outcome of CML patients. TKI has become the standard therapy for chronic phase (CP-) Ph+ Chronic myeloid leukemia (CML). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 3, 2016 Category: Hematology Authors: M. Massoud, F. Nasr, R. Sakr, J. Hawi, F. Kerbage, G. Chahine Source Type: research

Consolidative radioimmunotherapy after chemoimmunotherapy in patients with histologic transformation of indolent non Hodgkin lymphoma
We examined our experience using radioimmunotherapy consolidation for histologic transformation in 21 patients ineligible for more aggressive therapies, and described prolonged overall and progression free survival. The survival outcomes compare favorably to historical data and the approach has acceptable toxicity in a frail patient population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 1, 2016 Category: Hematology Authors: Patrick M. Reagan, Andrea Baran, Jennifer L. Kelly, Paul M. Barr, Carla Casulo, Vaseem U. Chengazi, Jonathan W. Friedberg Tags: Original Study Source Type: research

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor
The clinical prognostic factors during treatment are very important in chronic myeloid leukemia. An early molecular response and the halving time of BCR-ABL1 might be highly predictive of the outcome. A retrospective analysis of a cohort of 50 patients showed the importance of a very early molecular response in identifying subjects with favorable outcomes, using ABL1 as the control gene for the analysis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: Carmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, Enrico Gottardi, Paola Berchialla, Bruno Di Gioacchino, Francesca Crasto, Roberta Lorenzatti, Alessandro Volpengo, Filomena Daraio, Cristina Fantino, Giuseppe Saglio Tags: SOHO Supplement 2016 Source Type: research

Human Herpesvirus Type 8-positive Multicentric Castleman Disease
Castleman disease (CD) is rare lymphoproliferative disorder with local lesionsor with multiple lessions (multicentric CD [MCD] –usually with plasma cell or mix cell morphology). Patients with human herpesvirus (HHV) type 8-positive MCD were included in a separate group owing to its extremely aggressive course and the high risk of transformation into HHV8+ plasmablastic lymphoma. At our hematologic center, from 1996 to the present, the clinical and morphologic features of 87 patients with CD were analyzed. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: Anait L. Melikyan, Elena K. Egorova, Hunan L. Julhakyan, Alla L. Kovrigina, Valeriy G. Savchenko Tags: SOHO Supplement 2016 Source Type: research

Progressive Transformation of Germinal Centers: Single-Center Experience of 33 Turkish Patients
We reviewed the records of patients with progressive transformation of germinal centers (PTGCs) to determine the clinicopathologic features and association with any type of lymphoma. We determined that PTGCs can be seen simultaneously with lymphoma and during the follow-up of patients with lymphoma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: Melda C ömert Özkan, Nazan Özsan, Mine Hekimgil, Güray Saydam, Mahmut Töbü Tags: SOHO Supplement 2016 Source Type: research

A Single-center Experience in Splenic Diffuse Red Pulp Lymphoma Diagnosis
The World Health Organization 2008 classification highlighted a new nosology —splenic diffuse red pulp lymphoma (SDRPL) with clinical and laboratory features similar to both splenic marginal zone lymphoma and hairy cell leukemia (HCL) and variant form of HCL. Experience of hematologists on the diagnosis and differential diagnosis of SDRPL is extremely limited. The aim of o ur report was to characterize the clinical and immunomorphologic features of SDRPL on our own observations. During 2013-2014, in National Research Center for Hematology, 87 spleen specimens removed from various B-cell lymphomas were analyzed. (Sour...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: Hunan L. Julhakyan, L.S. Al-Radi, T.N. Moiseeva, K.I. Danishyan, A.M. Kovrigina, S.M. Glebova, S.A. Lugovskaya, V.N. Dvirnik, A.N. Khvastunova, I.A. Yakutik, V.G. Savchenko Tags: SOHO Supplement 2016 Source Type: research

High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing  Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
We examined the expression of HDM4 and the short splicing variant, HDM4-S, in bone marrow samples obtained from 85 and 23 patients with AML  and MDS, respectively, and 18 negative tumor staging bone marrow samples (used as the control). Immunohistochemical staining showed that HDM4 was overexpressed in 78 AML cases (92%) and 12 MDS cases (52%) compared with 1 stressed bone marrow sample (6%). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: Xin Han, L. Jeffrey Medeiros, Yu Helen Zhang, M. James You, Michael Andreeff, Marina Konopleva, Carlos E. Bueso-Ramos Tags: SOHO Supplement 2016 Source Type: research

Human Herpesvirus Type 8-associated Large B-cell Lymphoma: A Nonserous Extracavitary Variant of Primary Effusion Lymphoma in an HIV-infected Man: A Case Report and Review of the Literature
Human herpesvirus type 8-associated large B-cell lymphoma is a variant of primary effusion lymphoma that is both solid and extracavitary. It has immunoblastic and/or anaplastic morphologic features and a distinct immunohistochemical staining pattern. It might also have a different clinical presentation from classic human immunodeficiency virus-associated primary effusion lymphoma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: William R. Foster, Alina Bischin, Russell Dorer, David M. Aboulafia Tags: Original Study Source Type: research

High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
We examined the expression of HDM4 and the short splicing variant, HDM4-S, in bone marrow samples obtained from 85 and 23 patients with AML and MDS, respectively, and 18 negative tumor staging bone marrow samples (used as the control). Immunohistochemical staining showed that HDM4 was overexpressed in 78 AML cases (92%) and 12 MDS cases (52%) compared with 1 stressed bone marrow sample (6%). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: Xin Han, L. Jeffrey Medeiros, Yu Helen Zhang, M. James You, Michael Andreeff, Marina Konopleva, Carlos E. Bueso-Ramos Tags: SOHO Supplement 2015 Source Type: research

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor
The clinical prognostic factors during treatment are very important in chronic myeloid leukemia. An early molecular response and the halving time of BCR-ABL1 might be highly predictive of the outcome. A retrospective analysis of a cohort of 50 patients showed the importance of a very early molecular response in identifying subjects with favorable outcomes, using ABL1 as the control gene for the analysis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: Carmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, Enrico Gottardi, Paola Berchialla, Bruno Di Gioacchino, Francesca Crasto, Roberta Lorenzatti, Alessandro Volpengo, Filomena Daraio, Cristina Fantino, Giuseppe Saglio Tags: SOHO Supplement 2015 Source Type: research

A Single-center Experience in Splenic Diffuse Red Pulp Lymphoma Diagnosis
The World Health Organization 2008 classification highlighted a new nosology—splenic diffuse red pulp lymphoma (SDRPL) with clinical and laboratory features similar to both splenic marginal zone lymphoma and hairy cell leukemia (HCL) and variant form of HCL. Experience of hematologists on the diagnosis and differential diagnosis of SDRPL is extremely limited. The aim of our report was to characterize the clinical and immunomorphologic features of SDRPL on our own observations. During 2013-2014, in National Research Center for Hematology, 87 spleen specimens removed from various B-cell lymphomas were analyzed. (Source...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: Hunan L. Julhakyan, L.S. Al-Radi, T.N. Moiseeva, K.I. Danishyan, A.M. Kovrigina, S.M. Glebova, S.A. Lugovskaya, V.N. Dvirnik, A.N. Khvastunova, I.A. Yakutik, V.G. Savchenko Tags: SOHO Supplement 2015 Source Type: research

Human Herpesvirus Type 8-positive Multicentric Castleman Disease
Castleman disease (CD) is rare lymphoproliferative disorder with local lesionsor with multiple lessions (multicentric CD [MCD]–usually with plasma cell or mix cell morphology). Patients with human herpesvirus (HHV) type 8-positive MCD were included in a separate group owing to its extremely aggressive course and the high risk of transformation into HHV8+ plasmablastic lymphoma. At our hematologic center, from 1996 to the present, the clinical and morphologic features of 87 patients with CD were analyzed. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2016 Category: Hematology Authors: Hunan L. Julhakyan, Anait L. Melikyan, Elena K. Egorova, Alla L. Kovrigina, Valeriy G. Savchenko Tags: SOHO Supplement 2015 Source Type: research